Gradient Investments LLC Grows Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Gradient Investments LLC grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 133.6% in the 2nd quarter, Holdings Channel.com reports. The fund owned 619 shares of the biopharmaceutical company’s stock after buying an additional 354 shares during the period. Gradient Investments LLC’s holdings in Gilead Sciences were worth $42,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Private Wealth Management Group LLC acquired a new stake in Gilead Sciences during the 4th quarter worth about $29,000. Palisade Asset Management LLC purchased a new position in Gilead Sciences in the 1st quarter valued at about $29,000. Sachetta LLC acquired a new stake in Gilead Sciences in the 4th quarter worth about $30,000. Gladius Capital Management LP acquired a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $34,000. Finally, Frank Rimerman Advisors LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter worth approximately $36,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total value of $406,150.20. Following the completion of the sale, the insider now directly owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $68.63, for a total transaction of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 5,490 shares of the stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the sale, the insider now owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Analyst Ratings Changes

GILD has been the topic of several recent research reports. Evercore ISI raised shares of Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Cantor Fitzgerald restated a “neutral” rating and issued a $70.00 price target on shares of Gilead Sciences in a research report on Friday, August 9th. BMO Capital Markets lifted their price target on Gilead Sciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Thursday. Finally, Barclays reduced their price target on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a research note on Monday, April 29th. Twelve analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $81.94.

Gilead Sciences Trading Down 0.8 %

NASDAQ:GILD opened at $73.78 on Friday. The stock has a 50-day simple moving average of $70.80 and a 200-day simple moving average of $70.26. The stock has a market cap of $91.92 billion, a P/E ratio of 204.94, a P/E/G ratio of 3.37 and a beta of 0.18. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $87.86. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.94 and a current ratio of 1.08.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be given a dividend of $0.77 per share. The ex-dividend date is Friday, September 13th. This represents a $3.08 annualized dividend and a dividend yield of 4.17%. Gilead Sciences’s dividend payout ratio is presently 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.